Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04843319 · ClinicalTrials.gov registry record · Phase 1
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
A Phase 1 study, sponsored by Veru.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04843319 is a Phase 1 study that was terminated before completion, run by Veru. The registered enrollment target is 24 participants.
The verdict
NCT04843319, a Phase 1 study, was terminated before completion, sponsored by Veru.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.
Interventions
- DRUG VERU-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2023-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04843319
The ClinicalTrials.gov registry entry for NCT04843319 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veru, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VERU-100 is the first listed.
NCT04843319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04843319 about?
NCT04843319 is a clinical study titled "To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer". To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.
What is the current status of trial NCT04843319?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-06-09. Estimated completion is 2023-01-19.
What interventions are being tested in trial NCT04843319?
The interventions under investigation include: VERU-100 (DRUG).
Who is sponsoring clinical trial NCT04843319?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.